Vanda Pharmaceuticals Inc.
VNDA
$6.42
$0.152.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 51.72M | 57.22M | 56.26M | 52.59M | 50.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.72M | 57.22M | 56.26M | 52.59M | 50.04M |
| Cost of Revenue | 3.16M | 3.83M | 2.95M | 2.74M | 3.52M |
| Gross Profit | 48.56M | 53.38M | 53.30M | 49.85M | 46.52M |
| SG&A Expenses | 68.36M | 62.98M | 60.27M | 64.62M | 50.08M |
| Depreciation & Amortization | 1.99M | 1.75M | 1.75M | 1.75M | 1.75M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 101.94M | 97.57M | 87.54M | 91.09M | 91.07M |
| Operating Income | -50.22M | -40.35M | -31.28M | -38.50M | -41.03M |
| Income Before Tax | -48.42M | -38.00M | -28.39M | -34.89M | -37.37M |
| Income Tax Expenses | 143.00K | 103.19M | -5.80M | -7.68M | -7.87M |
| Earnings from Continuing Operations | -48.57M | -141.19M | -22.59M | -27.21M | -29.49M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.57M | -141.19M | -22.59M | -27.21M | -29.49M |
| EBIT | -50.22M | -40.35M | -31.28M | -38.50M | -41.03M |
| EBITDA | -47.96M | -38.30M | -29.23M | -36.49M | -39.05M |
| EPS Basic | -0.82 | -2.39 | -0.38 | -0.46 | -0.50 |
| Normalized Basic EPS | -0.51 | -0.42 | -0.30 | -0.37 | -0.40 |
| EPS Diluted | -0.82 | -2.39 | -0.38 | -0.46 | -0.50 |
| Normalized Diluted EPS | -0.51 | -0.42 | -0.30 | -0.37 | -0.40 |
| Average Basic Shares Outstanding | 59.46M | 59.10M | 59.09M | 58.99M | 58.53M |
| Average Diluted Shares Outstanding | 59.46M | 59.10M | 59.09M | 58.99M | 58.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |